Citadel Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Citadel Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78M	Buy	+680,043	New	+$2.25M	﹤0.01%	5832
2025 Q3	–	Sell	-92,361	Closed	-$264K	–	13678
2025 Q2	$301K	Buy	+92,361	New	+$232K	﹤0.01%	9818
2023 Q3	–	Sell	-25	Closed	-$83	–	14820
2023 Q2	$119	Hold	25	–	–	﹤0.01%	14217
2023 Q1	$163	Sell	25 -1,231	-98%	-$12.5K	﹤0.01%	14559
2022 Q4	$13.9K	Buy	+1,256	New	+$12.7K	﹤0.01%	13414
2022 Q3	–	Sell	-9,167	Closed	-$61.8K	–	13277
2022 Q2	$55K	Buy	+9,167	New	+$120K	﹤0.01%	11870
2021 Q4	–	Sell	-13,509	Closed	-$975K	–	14443
2021 Q3	$1.25M	Buy	+13,509	New	+$1.76M	﹤0.01%	7554

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors's NRXP Position: Q2 2026 in Review

Citadel Advisors opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 680,043 shares worth $2.78M. The stake represents ﹤0.01% of the portfolio and ranks #5832 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NRXP as recently as Q2 2025.

Citadel Advisors first reported a position in NRXP in Q3 2021 and has held it in 7 quarters since. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

Citadel Advisors held 680,043 shares of NRX Pharmaceuticals worth $2.78M as of Q2 2026.
NRX Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
NRX Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5832 holding.
Citadel Advisors first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 7 quarters since.
47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.